Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Group 1 - Phathom Pharmaceuticals, Inc. (PHAT) shares have increased by 184.1% in the past four weeks, closing at $8.92, with a mean price target of $18.50 indicating a potential upside of 107.4% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $8.09, where the lowest estimate is $5 (44% decline) and the highest is $28 (213.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 16% over the last 30 days, with one estimate increasing and no negative revisions [12] - PHAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]